New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors

Abdel-Razaq W, Kendall DA, Bates TE (2011) The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria. Neurochem Res 36(2):327–338PubMedCrossRef

Albrecht P, Lewerenz J, Dittmer S, Noack R, Maher P, Methner A (2010) Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc- as a neuroprotective drug target. CNS Neurol Disord Drug Targets 9:373–382PubMed

Ames BN (2003) Delaying the mitochondrial decay of aging-a metabolic tune-up. Alzheimer Dis Assoc Disord 17(Suppl 2):S54–S57PubMedCrossRef

Amminger GP, Schäfer MR, Klier CM, Slavik J-M, Holzer I, Holub M, Goldstone S, Whitford TJ, Berk M (2011) Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high risk individuals. Mol Psychiatry (in press)

Anisman H, Merali Z (1999) Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 461:199–233PubMedCrossRef

Anttila S, Huuhka K, Huuhka M, Rontu R, Hurme M, Leinonen E, Lehtimaki T (2007) Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. J Neural Transm 114(8):1065–1068PubMedCrossRef

Arakawa H, Blandino P Jr, Deak T (2009) Central infusion of interleukin-1 receptor antagonist blocks the reduction in social behavior produced by prior stressor exposure. Physiol Behav 98(1–2):139–146PubMedCrossRef

Atlante A, Calissano P, Bobba A, Giannattasio S, Marra E, Passarella S (2001) Glutamate neurotoxicity, oxidative stress and mitochondria. FEBS Lett 497(1):1–5PubMedCrossRef

Bachmann RF, Wang Y, Yuan P, Zhou R, Li X, Alesci S, Du J, Manji HK (2009) Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol 12(6):805–822PubMedCrossRef

Baker DA, Xi ZX, Shen H et al (2002) The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci 22:9134–9141PubMed

Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, Kalivas PW (2003) Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 6:743–749PubMedCrossRef

Balaban RS, Nemoto S, Finkel T (2005) Mitochondria, oxidants, and aging. Cell 120(4):483–495PubMedCrossRef

Bao Z, Lim S, Liao W, Lin Y, Thiemermann C, Leung BP et al (2007) Glycogen synthase kinase-3beta inhibition attenuates asthma in mice. Am J Respir Crit Care Med 176:431–438PubMedCrossRef

Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D (2006) Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 6(11):3414–3425PubMedCrossRef

Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC, Gainetdinov RR, Caron MG (2008) Role of GSK3beta in behavioural abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 105:1333–1338PubMedCrossRef

Beckman KB, Ames BN (1996) Detection and quantification of oxidative adducts of mitochondrial DNA. Methods Enzymol 264:442–453PubMedCrossRef

Ben-Shachar D, Karry R (2008) Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS One 3(11):e3676PubMedCrossRef

Berk M, Wadee AA, Kuschke RH, O’Neill-Kerr A (1997) Acute phase proteins in major depression. J Psychosom Res 43(5):529–534PubMedCrossRef

Berk M, Mitchell VS, Plein H (1998) The platelet intracellular calcium response to serotonin in subsyndromal depression. Int Clin Psychopharmacol 13(3):107–110PubMedCrossRef

Berk M, Plein H, Ferreira D (2001) Platelet glutamate receptor supersensitivity in major depressive disorder. Clin Neuropharmacol 24(3):129–132PubMedCrossRef

Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI (2008) N-Acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol Psychiatry 64(6):468–475PubMedCrossRef

Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, Cobb H, Bush AI, Schapkaitz I, Dodd S, Malhi GS (2011a) The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 135(1–3):389–394PubMedCrossRef

Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B, Magalhães PV, Amminger P, McGorry P, Malhi GS (2011b) Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35(3):804–817PubMedCrossRef

Beurel E (2011) Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases. Front Mol Neurosci 4:18PubMedCrossRef

Beurel E, Jope RS (2008) Differential regulation of STAT family members by glycogen synthase kinase-3. J Biol Chem 283:21934–21944PubMedCrossRef

Beurel E, Jope RS (2010) Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes. Neuroscience 169(3):1063–1070PubMedCrossRef

Bilici M, Efe H, Köroğlu MA, Uydu HA, Bekaroğlu M, Değer O (2001) Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 64(1):43–51PubMedCrossRef

Bjarnason I, Takeuchi K (2009) Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J Gastroenterol 44(Suppl 19):23–29PubMedCrossRef

Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H, Maes M (2002) Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 22(1):86–90PubMedCrossRef

Boyle JJ, Johns M, Lo J, Chiodini A, Ambrose N, Evans PC, Mason JC, Haskard DO (2011) Heme induces heme oxygenase 1 via Nrf2: role in the homeostatic macrophage response to intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 31(11):2685–2691PubMedCrossRef

Brand MD, Nicholls DG (2011) Assessing mitochondrial dysfunction in cells. Biochem J 435(2):297–312PubMedCrossRef

Brown ES, Woolston D, Frol A, Bobadilla L, Khan DA, Hanczyc M, Rush AJ, Fleckenstein J, Babcock E, Cullum CM (2004) Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biol Psychiatry 55(5):538–545PubMedCrossRef

Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB (2006) A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol 6(6):903–907PubMedCrossRef

Búrigo M, Roza CA, Bassani C, Fagundes DA, Rezin GT, Feier G, Dal-Pizzol F, Quevedo J, Streck EL (2006) Effect of electroconvulsive shock on mitochondrial respiratory chain in rat brain. Neurochem Res 31(11):1375–1379PubMedCrossRef

Butler MG, Dasouki M, Bittel D, Hunter S, Naini A, DiMauro S (2003) Coenzyme Q10 levels in Prader–Willi syndrome: comparison with obese and non-obese subjects. Am J Med Genet A 119A(2):168–171PubMedCrossRef

Calkins MJ, Jakel RJ, Johnson DA, Chan K, Kan YW, Johnson JA (2005) Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci USA 102(1):244–249PubMedCrossRef

Campbell S, MacQueen G (2006) An update on regional brain volume differences associated with mood disorders. Curr Opin Psychiatry 19(1):25–33PubMedCrossRef

Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655–1657PubMedCrossRef

Catena-Dell’Osso M, Bellantuono C, Consoli G, Baroni S, Rotella F, Marazziti D (2011) Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development? Curr Med Chem 18(2):245–255PubMedCrossRef

Chen G, Huang LD, Jiang YM, Manji HK (1999) The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72(3):1327–1330PubMedCrossRef

Chen K, Gunter K, Maines MD (2000) Neurons overexpressing heme oxygenase-1 resist oxidative stress-mediated cell death. J Neurochem 75:304–312PubMedCrossRef

Chen G, Shi J, Hu Z et al (2008) Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: a potential neuroprotective mechanism of N-acetylcysteine. Mediators Inflamm 2008:716458PubMedCrossRef

Chen Y, Jiang T, Chen P, Ouyang J, Xu G, Zeng Z, Sun Y (2011) Emerging tendency towards autoimmune process in major depressive patients: a novel insight from Th17 cells. Psychiatry Res 188(2):224–230PubMedCrossRef

Connor TJ, Song C, Leonard BE, Merali Z, Anisman H (1998) An assessment of the effects of central interleukin-1beta, -2, -6, and tumor necrosis factor-alpha administration on some behavioural, neurochemical, endocrine and immune parameters in the rat. Neuroscience 84(3):923–933PubMedCrossRef

Correa F, Mallard C, Nilsson M, Sandberg M (2011) Activated microglia decrease histone acetylation and Nrf2-inducible anti-oxidant defence in astrocytes: restoring effects of inhibitors of HDACs, p38 MAPK and GSK3β. Neurobiol Dis 44:142–151PubMed

Crane FL (2001) Biochemical functions of coenzyme Q10. J Am Coll Nutr 20(6):591–598PubMed

Cumurcu BE, Ozyurt H, Etikan I, Demir S, Karlidag R (2009) Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry Clin Neurosci 63(5):639–645PubMedCrossRef

Cuzzocrea S, Crisafulli C, Mazzon E, Esposito E, Muia C, Abdelrahman M et al (2006a) Inhibition of glycogen synthase kinase-3beta attenuates the development of carrageenan-induced lung injury in mice. Br J Pharmacol 149:687–702PubMedCrossRef

Cuzzocrea S, Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muia C et al (2006b) Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma. J Pharmacol Exp Ther 318:79–89PubMedCrossRef

Cuzzocrea S, Mazzon E, Di Paola R, Muia C, Crisafulli C, Dugo L et al (2006c) Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin Immunol 120:57–67PubMedCrossRef

Cuzzocrea S, Di Paola R, Mazzon E, Crisafulli C, Genovese T, Muia C et al (2007a) Glycogen synthase kinase 3beta inhibition reduces the development of nonseptic shock induced by zymosan in mice. Shock 27:97–107PubMedCrossRef

Cuzzocrea S, Genovese T, Mazzon E, Esposito E, Muia C, Abdelrahman M et al (2007b) Glycogen synthase kinase-3beta inhibition attenuates the development of Bleomycin-induced lung injury. Int J Immunopathol Pharmacol 20:619–630PubMed

Cuzzocrea S, Mazzon E, Esposito E, Muia C, Abdelrahman M, Di Paola R et al (2007c) Glycogen synthase kinase-3beta inhibition attenuates the development of ischaemia/reperfusion injury of the gut. Intense Care Med 33:880–893CrossRef

Daley-Yates PT, Powell AP, Smith LL (1988) Pulmonary indoleamine 2,3-dioxygenase activity and its significance in the response of rats, mice, and rabbits to oxidative stress. Toxicol Appl Pharmacol 96(2):222–232PubMedCrossRef

Dang H, Chen Y, Liu X, Wang Q, Wang L, Jia W, Wang Y (2009) Antidepressant effects of ginseng total saponins in the forced swimming test and chronic mild stress models of depression. Prog Neuropsychopharmacol Biol Psychiatry 33(8):1417–1424PubMedCrossRef

De Sarno P, Axtell RC, Raman C, Roth KA, Alessi DR, Jope RS (2008) Lithium reverts and ameliorates experimental autoimmune encephalomyelitis. J Immunol 181:338–345PubMed

de Vries HE, Witte M, Hondius D, Rozemuller AJ, Drukarch B, Hoozemans J, van Horssen J (2008) Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease? Free Radic Biol Med 45(10):1375–1383PubMedCrossRef

Dean O, Giorlando F, Berk M (2011) N-Acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 36(2):78–86PubMed

Dimopoulos N, Piperi C, Psarra V, Lea RW, Kalofoutis A (2008) Increased plasma levels of 8-iso-PGF2alpha and IL-6 in an elderly population with depression. Psychiatry Res 161(1):59–66PubMedCrossRef

Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67(5):446–457PubMedCrossRef

Dragicevic N, Bradshaw PC, Mamcarz M, Lin X, Wang L, Cao C, Arendash GW (2011) Long-term electromagnetic field treatment enhances brain mitochondrial function of both Alzheimer’s transgenic mice and normal mice: a mechanism for electromagnetic field-induced cognitive benefit? Neuroscience 185:135–149PubMedCrossRef

Dubovsky S (2010) Depression is an inflammatory disease. J Watch Psychiatry 67:446

Dugo L, Abdelrahman M, Murch O, Mazzon E, Cuzzocrea S, Thiemermann C (2006) Glycogen synthase kinase-3beta inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation. Shock 25:485–491PubMedCrossRef

Duman RS (2004) Depression: a case of neuronal life and death? Biol Psychiatry 56(3):140–145PubMedCrossRef

Dutton PL, Ohnishi T, Darrouzet E, Leonard MA, Sharp RE, Cibney BR, Daldal F, Moser CC (2000) Coenzyme Q oxidation reduction reactions in mitochondrial electron transport. In: Kagan VE, Quinn PJ (eds) Coenzyme Q: molecular mechanisms in health and disease. CRC Press, Boca Raton, pp 65–82

Dwivedi Y, Rizavi HS, Roberts RC, Conley RC, Tamminga CA, Pandey GN (2011) Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem 77(3):916–928CrossRef

Edwards R, Peet M, Shay J, Horrobin D (1998) Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 48(2–3):149–155PubMedCrossRef

Eren I, Naziroglu M, Demirdas A (2007a) Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem Res 32(7):1188–1195PubMedCrossRef

Eren I, Naziroglu M, Demirdas A, Celik O, Uguz AC, Altunbasak A, Ozmen I, Uz E (2007b) Venlafaxine modulates depression-induced oxidative stress in brain and medulla of rat. Neurochem Res 32(3):497–505PubMedCrossRef

Fattal O, Budur K, Vaughan AJ, Franco K (2006) Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics 47(1):1–7PubMedCrossRef

Fišar Z, Hroudová J (2010) Intracellular signalling pathways and mood disorders. Folia Biol (Praha) 56(4):135–148

Forlenza MJ, Miller GE (2006) Increased serum levels of 8-hydroxy-2′-deoxyguanosine in clinical depression. Psychosom Med 68(1):1–7PubMedCrossRef

Fuchs E, Czeh B, Kole MH, Michaelis T, Lucassen PJ (2004) Alterations of neuroplasticity in depression: the hippocampus and beyond. Eur Neuropsychopharmacol 14(Suppl 5):S481–S490PubMedCrossRef

Gałecki P, Szemraj J, Bieńkiewicz M, Zboralski K, Gałecka E (2009a) Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 24:277–286PubMedCrossRef

Gałecki P, Szemraj J, Bieńkiewicz M, Florkowski A, Gałecka E (2009b) Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol Rep 61(3):436–447PubMed

Gao HK, Yin Z, Zhou N, Feng XY, Gao F, Wang HC (2008) Glycogen synthase kinase-3 inhibition protects the heart from acute ischemia–reperfusion injury via inhibition of inflammation and apoptosis. J Cardiovasc Pharmacol 52:286–292PubMedCrossRef

Garcia LS, Comim CM, Valvassori SS, Réus GZ, Barbosa LM, Andreazza AC, Stertz L, Fries GR, Gavioli EC, Kapczinski F, Quevedo J (2008) Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 32(1):140–144PubMedCrossRef

Gardner A, Boles RG (2008a) Symptoms of somatization as a rapid screening tool for mitochondrial dysfunction in depression. Biopsychosoc Med 2:7PubMedCrossRef

Gardner A, Boles RG (2008b) Mitochondrial energy depletion in depression with somatization. Psychother Psychosom 77(2):127–129PubMedCrossRef

Gardner A, Boles RG (2011) Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog. Neuro Psychopharmacol Biol Psychiatry 35(3):730–743CrossRef

Gardner A, Johansson A, Wibom R, Nennesmo I, von Döbeln U, Hagenfeldt L, Hällström T (2003) Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J Affect Disord 76(1–3):55–68PubMedCrossRef

Gawryluk JW, Wang JF, Andreazza AC, Shao L, Yatham LN, Young LT (2011) Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. Int J Neuropsychopharmacol 14(8):1069–1074PubMedCrossRef

Gere-Paszti E, Jakus J (2009) The effect of N-acetylcysteine on amphetamine-mediated dopamine release in rat brain striatal slices by ion-pair reversed-phase high performance liquid chromatography. Biomed Chromatogr 23:658–664PubMedCrossRef

Gould TD, Manji HK (2005) Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30:1223–1237PubMed

Gould TD and Manji HK (2006) Glycogen synthase kinase 3: a target for novel mood disorder treatments. In: Wang B (ed) Glycogen synthase kinase 3 (GSK-3) and its inhibitors-drug discovery and development, Chap 7. Wiley Series in Drug Discovery and Development, New Jersey, pp 125–154

Greco T, Fiskum G (2010) Neuroprotection through stimulation of mitochondrial antioxidant protein expression. J Alzheimers Dis 20(Suppl 2):S427–S437PubMed

Guha M, Mackman N (2002) The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 277:32124–32132PubMedCrossRef

Gutiérrez-Pérez A, Cortés-Rojo C, Noriega-Cisneros R, Calderón-Cortés E, Manzo-Avalos S, Clemente-Guerrero M, Godinez-Hernández D, Boldogh I, Saavedra-Molina A (2011) Protective effects of resveratrol on calcium-induced oxidative stress in rat heart mitochondria. J Bioenerg Biomembr 43(2):101–107PubMedCrossRef

Halestrap AP, McStay GP, Clarke SJ (2002) The permeability transition pore complex: another view. Biochimie 84(2–3):153–166PubMedCrossRef

Halestrap AP, Clarke SJ, Javadov SA (2004) Mitochondrial permeability transition pore opening during myocardial reperfusion—a target for cardioprotection. Cardiovasc Res 61(3):372–385PubMedCrossRef

Hannestad J, Dellagioia N, Bloch M (2011) The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36(12):2452–2459PubMedCrossRef

Harvey CJ, Thimmulappa RK, Singh A, Blake DJ, Ling G, Wakabayashi N, Fujii J, Myers A, Biswal S (2009) Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic Biol Med 46(4):443–445PubMedCrossRef

Hashioka S, Klegeris A, Monji A, Kato T, Sawada M, McGeer PL, Kanba S (2007) Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol 206(1):33–42PubMedCrossRef

Herken H, Gurel A, Selek S, Armutcu F, Ozen ME, Bulut M, Kap O, Yumru M, Savas HA, Akyol O (2007) Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 38(2):247–252PubMedCrossRef

Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR (2000) Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406:86–90PubMedCrossRef

Hroudová J, Fišar Z (2011) Connectivity between mitochondrial functions and psychiatric disorders. Psychiatry Clin Neurosci 65(2):130–141PubMedCrossRef

Hu X, Paik PK, Chen J, Yarilina A, Kockeritz L, Lu TT et al (2006) IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 24:563–574PubMedCrossRef

Huang WC, Lin YS, Wang CY, Tsai CC, Tseng HC, Chen CL, Lu PJ, Chen PS, Qian L, Hong JS, Lin CF (2009) Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells. Immunology 128(1 Suppl):e275–e286PubMedCrossRef

Hubbs AF, Benkovic SA, Miller DB, O’Callaghan JP, Battelli L, Schwegler-Berry D, Ma Q (2007) Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2. Am J Pathol 170(6):2068–2076PubMedCrossRef

Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, Cass WA, Sullivan PG, Bing G (2007) Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 100(5):1375–1386PubMedCrossRef

Hybertson BM, Gao B, Bose SK, McCord JM (2011) Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol Aspects Med 2011 Oct 15 (Epub ahead of print)

Innamorato NG, Rojo AI, García-Yagüe AJ, Yamamoto M, de Ceballos ML, Cuadrado A (2008) The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 181(1):680–689PubMed

Irie M, Miyata M, Kasai H (2005) Depression and possible cancer risk due to oxidative DNA damage. J Psychiatr Res 39(6):553–560PubMedCrossRef

Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236(2):313–322PubMedCrossRef

Ivanov II, Mckenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17 + Thelper cells. Cell 126:1121–1133PubMedCrossRef

Jain AK, Jaiswal AK (2007) GSK-3β acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J Biol Chem 282(22):16502–16510PubMedCrossRef

Jeng JY, Lee WH, Tsai YH, Chen CY, Chao SY, Hsieh RH (2009) Functional modulation of mitochondria by eicosapentaenoic acid provides protection against ceramide toxicity to C6 glioma cells. J Agric Food Chem 57(24):11455–11462PubMedCrossRef

Jiang Y, Deacon R, Anthony DC, Campbell SJ (2008) Inhibition of peripheral TNF can block the malaise associated with CNS inflammatory diseases. Neurobiol Dis 32(1):125–132PubMedCrossRef

Jimerson DC, Post RM, Carman JS, van Kammen DP, Wood JH, Goodwin FK, Bunney WE Jr (1979) CSF calcium: clinical correlates in affective illness and schizophrenia. Biol Psychiatry 14(1):37–51PubMed

Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, Chen PC (2008) The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann NY Acad Sci 1147:61–69PubMedCrossRef

Jones SP, Teshima Y, Akao M, Marbán E (2003) Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res 93(8):697–699PubMedCrossRef

Jope RS (1999) Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 4(2):117–128PubMedCrossRef

Jope RS (2011) Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci 4:16PubMedCrossRef

Jou SH, Chiu NY, Liu CS (2009) Mitochondrial dysfunction and psychiatric disorders. Chang Gung Med J 32(4):370–379PubMed

Kahl KG, Kruse N, Faller H, Weiss H, Rieckmann P (2002) Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 27(6):671–681PubMedCrossRef

Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H (2004) Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 55(8):781–784PubMedCrossRef

Kanninen K, White AR, Koistinaho J, Malm T (2011) Targeting glycogen synthase kinase-3β for therapeutic benefit against oxidative stress in Alzheimer’s disease: involvement of the Nrf2-ARE pathway. Int J Alzheimers Dis 2011:985085PubMed

Karry R, Klein E, Ben Shachar D (2004) Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol Psychiatry 55:676–684PubMedCrossRef

Kaspar JW, Niture SK, Jaiswal AK (2009) Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med 47:1304–1309PubMedCrossRef

Kato T (2007) Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. CNS Drugs 21(1):1–11PubMedCrossRef

Kato T (2008) Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. Cell Calcium 44(1):92–102PubMedCrossRef

Kato T, Kato N (2000) Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2(3 Pt 1):180–190PubMedCrossRef

Katyare SS, Rajan RR (1995) Effect of long-term in vivo treatment with imipramine on the oxidative energy metabolism in rat brain mitochondria. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 112(3):353–357PubMedCrossRef

Khan M, Sekhon B, Jatana M et al (2004) Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. J Neurosci Res 76:519–527PubMedCrossRef

Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R (2003) Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 8(6):365–370PubMedCrossRef

Kirsch I (2009) Antidepressants and the placebo response. Epidemiol Psychiatr Soc 18(4):318–322

Klein PS, Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93(16):8455–8459PubMedCrossRef

Klementiev B, Novikova T, Novitskaya V, Walmod PS, Dmytriyeva O, Pakkenberg B, Berezin V, Bock E (2007) A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35. Neuroscience 145(1):209–224PubMedCrossRef

Kodydková J, Vávrová L, Zeman M, Jirák R, Macásek J, Stanková B, Tvrzická E, Zák A (2009) Antioxidative enzymes and increased oxidative stress in depressive women. Clin Biochem 42(13–14):1368–1374PubMedCrossRef

Koo JW, Duman RS (2008) IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA 105(2):751–756PubMedCrossRef

Kroemer G, Zamzami N, Susin SA (1997) Mitochondrial control of apoptosis. Immunol Today 18(1):44–51PubMedCrossRef

Kubera M, Symbirtsev A, Basta-Kaim A, Borycz J, Roman A, Papp M, Claesson M (1996) Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Pol J Pharmacol 48(5):503–506PubMed

Kubera M, Holan V, Mathison R, Maes M (2000a) The effect of repeated amitriptyline and desipramine administration on cytokine release in C57BL/6 mice. Psychoneuroendocrinology 25(8):785–797PubMedCrossRef

Kubera M, Kenis G, Bosmans E, Zieba A, Dudek D, Nowak G, Maes M (2000b) Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol J Pharmacol 52(3):237–241PubMed

Kubera M, Simbirtsev A, Mathison R, Maes M (2000c) Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice. Psychiatry Res 96(3):255–266PubMedCrossRef

Kubera M, Obuchowicz E, Goehler L, Brzeszcz J, Maes M (2011) In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 35(3):744–759PubMedCrossRef

Kulkarni S, Dhir A, Akula KK (2009) Potentials of curcumin as an antidepressant. Sci World J 9:1233–1241CrossRef

Kumar P, Kumar A (2009) Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 33(1):100–108PubMedCrossRef

Lai J, Moxey A, Nowak G, Vashum K, Bailey K, McEvoy M (2011) The efficacy of zinc supplementation as therapy for depression: systematic review of randomized controlled trials. J Affect Disord. doi:10.1016/j.jad.2011.06.022

Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA (2005) Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. Biofactors 25(1–4):147–152PubMedCrossRef

Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H (2000) Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22(4):370–379PubMedCrossRef

Lante F, Meunier J, Guiramand J et al (2008) Late N-acetylcysteine treatment prevents the deficits induced in the offspring of dams exposed to an immune stress during gestation. Hippocampus 18:602–609PubMedCrossRef

Leconte C, Bihel E, Lepelletier FX, Bouët V, Saulnier R, Petit E, Boulouard M, Bernaudin M, Schumann-Bard P (2011) Comparison of the effects of erythropoietin and its carbamylated derivative on behaviour and hippocampal neurogenesis in mice. Neuropharmacology 60(2–3):354–364PubMedCrossRef

Lee KM, Kim YK (2006) The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol 6(8):1298–1304PubMedCrossRef

Lee JS, Surh YJ (2005) Nrf2 as a novel molecular target for chemoprevention. Cancer Lett 224(2):171–184PubMedCrossRef

Lee JM, Shih AY, Murphy TH, Johnson JA (2003) NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem 278(39):37948–37956PubMedCrossRef

Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Y, Crowe RA, Cascio WE, Bradham CA, Brenner DA, Herman B (1998) The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1366(1–2):177–196PubMed

Lenox RH, Hahn CG (2000) Overview of the mechanism of action of lithium in the brain: fifty-year update. J Clin Psychiatry 61(Suppl 9):5–15PubMed

Leonard BE, Maes M (2011) Mechanistic explanations how activated inflammatory, oxidative and nitrosative stress pathways cause depression. Neurosci Biobehav Rev (Epub ahead of print)

Li X, Bijur GN, Jope RS (2002) Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord 4(2):137–144PubMedCrossRef

Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS (2004) In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 29:1426–1431PubMedCrossRef

Li X, Rosborough KM, Friedman AB, Zhu W, Roth KA (2007) Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int J Neuropsychopharmacol 10:7–19PubMedCrossRef

Lin PY, Su KP (2007) A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 68(7):1056–1061PubMedCrossRef

Lipton P (1999) Ischemic cell death in brain neurons. Physiol Rev 79(4):1431–1568PubMed

Li-Smerin Y, Levitan ES, Johnson JW (2001) Free intracellular Mg(2+) concentration and inhibition of NMDA responses in cultured rat neurons. J Physiol 533:729–743PubMedCrossRef

Loix S, De Kock M, Henin P (2011) The anti-inflammatory effects of ketamine: state of the art. Acta Anaesthesiol Belg 62(1):47–58PubMed

Lorenzetti V, Allen NB, Fornito A, Yucel M (2009) Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. J Affect Disord 117(1–2):1–17PubMedCrossRef

Luchetti F, Canonico B, Betti M, Arcangeletti M, Pilolli F, Piroddi M, Canesi L, Papa S, Galli F (2010) Melatonin signaling and cell protection function. FASEB J 24(10):3603–3624PubMedCrossRef

MacAulay K, Woodgett JR (2008) Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of type 2 diabetes. Expert Opin Ther Targets 12(10):1265–1274PubMedCrossRef

Machado-Vieira R, Manji HK, Zarate CA Jr (2009) The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 11(Suppl 2):92–109PubMedCrossRef

Maes M (1995) Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19(1):11–38PubMedCrossRef

Maes M (2011) Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 35(3):664–675PubMedCrossRef

Maes M, Meltzer HY (1995) The serotonin hypothesis of major depression. selected chapters on mood disorders. In: Bloom F, Kupfer D (eds) Psychopharmacology. The fourth generation of progress. Raven Press, USA, pp 933–944

Maes M, Bosmans E, Suy E, Vandervorst C, De Jonckheere C, Raus J (1990) Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 24(3):115–120PubMedCrossRef

Maes M, Scharpé S, Van Grootel L, Uyttenbroeck W, Cooreman W, Cosyns P, Suy E (1992) Higher alpha 1-antitrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: further evidence for the existence of an inflammatory response during that illness. J Affect Disord 24(3):183–192PubMedCrossRef

Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H (1997a) Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9(11):853–858PubMedCrossRef

Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, Scharpé S (1997b) Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 66(1):1–11PubMedCrossRef

Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY (1999a) Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 85(3):275–291PubMedCrossRef

Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, De Jongh R, Bosmans E, Scharpe S (1999b) Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacol 20(4):370–379CrossRef

Maes M, De Vos N, Pioli R, Demedts P, Wauters A, Neels H, Christophe A (2000) Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defences in that illness. J Affect Disord 58(3):241–246PubMedCrossRef

Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E (2009a) Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome. Neuro Endocrinol Lett 30(6):715–722PubMed

Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E (2009b) Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocinol Lett 30:462–469

Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M (2009c) The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 24(1):27–53PubMedCrossRef

Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E (2010) Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J Affect Disord 125(1–3):287–294PubMedCrossRef

Maes M, Galecki P, Chang YS, Berk M (2011a) A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 35(3):676–692PubMedCrossRef

Maes M, Leonard B, Fernandez A, Kubera M, Nowak G, Veerhuis R, Gardner A, Ruckoanich P, Geffard M, Altamura C, Galecki P, Berk M (2011b) (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 35(3):659–663PubMedCrossRef

Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R (2011c) The new ‘5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 35(3):702–721PubMedCrossRef

Maes M, Mihaylova I, Kubera M, Leunis JC, Geffard M (2011d) IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 135(1–3):414–418PubMedCrossRef

Maes M, Mihaylova I, Kubera M, Ringel K (2011e) Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog Neuropsychopharmacol Biol Psychiatry. PMID: 21945535 (Epub ahead of print)

Maier SF, Watkins LR (1995) Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock. Brain Res 695(2):279–282PubMedCrossRef

Malberg JE, Monteggia LM (2008) VGF, a new player in antidepressant action? Sci Signal 1(18):pe19

Malhi GS, Berk M (2007) Does dopamine dysfunction drive depression? Acta Psychiatr Scand Suppl 433:116–124PubMedCrossRef

Malhi GS, Berk M (2011) Balance restored: lithium remains a safe and sound choice. Lancet (in press)

Malhotra D, Portales-Casamar E, Singh A, Srivastava S, Arenillas D, Happel C, Shyr C, Wakabayashi N, Kensler TW, Wasserman WW, Biswal S (2010) Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 38(17):5718–5734PubMedCrossRef

Martin M, Rehani K, Jope RS, Michalek SM (2005) Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6:777–7784PubMedCrossRef

Maurer IC, Schippel P, Volz HP (2009) Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord 11(5):515–522PubMedCrossRef

McKinnon MC, Yucel K, Nazarov A, MacQueen GM (2009) A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci (Meta Anal Rev) 34(1):41–54

Medina M, Avila J (2010) Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer’s disease. Curr Pharm Des 16(25):2790–2798PubMed

Medina M, Castro A (2008) Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr Opin Drug Discov Dev 11(4):533–543

Medina M, Wandosell FJ (2011) Deconstructing GSK-3: the fine regulation of its activity. Int J Alz Dis 479249. doi:10.4061/2011/479249

Medina M, Garrido JJ, Wandosell FJ (2011) Modulation of GSK-3 as a therapeutic strategy on Tau pathologies. Front Mol Neurosci 4:24PubMedCrossRef

Michel TM, Camara S, Tatschner T, Frangou S, Sheldrick AJ, Riederer P, Grunblatt E (2008) Increased xanthine oxidase in the thalamus and putamen in depression. World J Biol Psychiatry 12:1–7CrossRef

Miura T, Tanno M, Sato T (2010) Mitochondrial kinase signalling pathways in myocardial protection from ischaemia/reperfusion-induced necrosis. Cardiovasc Res 88(1):7–15PubMedCrossRef

Mizuno S, Yamamoto M, Sugawara I (2010) Significant reduction of granulomas in Nrf2-deficient mice infected with Mycobacterium tuberculosis. Indian J Tuberc 57(2):108–113PubMed

Moghaddam B (2002) Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry 51(10):775–787PubMedCrossRef

Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L (2001a) Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 69(6):942–949PubMedCrossRef

Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP (2001b) Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch Neurol 58(7):1081–1086PubMedCrossRef

Molina-Hernández M, Tellez-Alcántara NP, Pérez-García J, Olivera-Lopez JI, Jaramillo-Jaimes MT (2008) Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 32(2):380–386PubMedCrossRef

Moncrieff J, Wessely S, Hardy R (2004) Active placebos versus antidepressants for depression. Cochrane Database Syst Rev 1:CD003012

Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11(7):680–684PubMedCrossRef

Murphy MP (2009) Mitochondria—a neglected drug target. Curr Opin Investig Drugs 10(10):1022–1024PubMed

Nahon E, Israelson A, Abu-Hamad S, Varda SB (2005) Fluoxetine (Prozac) interaction with the mitochondrial voltage-dependent anion channel and protection against apoptotic cell death. FEBS Lett 579(22):5105–5110PubMedCrossRef

Nerland DE (2007) The antioxidant/electrophile response element motif. Drug Metab Rev 39(1):235–248PubMedCrossRef

Nestler EJ, Carlezon WA Jr (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59(12):1151–1159PubMedCrossRef

Nicholls DG (2008) Oxidative stress and energy crises in neuronal dysfunction. Ann NY Acad Sci 1147:53–60PubMedCrossRef

Nowak G, Siwek M, Dudek D, Zieba A, Pilc A (2003) Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol J Pharmacol 55:1143–1147PubMed

O’Shea JJ, Paul WE (2010) Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 327:1098–1102PubMedCrossRef

O’Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG (2007) Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 41(3–4):326–331PubMedCrossRef

O’Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, Lestage J, Castanon N, Kelley KW, Dantzer R (2009) Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette–Guerin. J Neurosci 29(13):4200–4209PubMedCrossRef

Owen AJ, Batterham MJ, Probst YC, Grenyer BF, Tapsell LC (2005) Low plasma vitamin E levels in major depression: diet or disease? Eur J Clin Nutr 59(2):304–306PubMedCrossRef

Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O (2004) Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 19(2):89–95PubMedCrossRef

Pae CU, Marks DM, Han C, Patkar AA (2008) Does minocycline have antidepressant effect? Biomed Pharmacother 62(5):308–311PubMedCrossRef

Paintlia MK, Paintlia AS, Khan M et al (2008) Modulation of peroxisome proliferator-activated receptor-alpha activity by N-acetyl cysteine attenuates inhibition of oligodendrocyte development in lipo-polysaccharide stimulated mixed glial cultures. J Neurochem 105:956–970PubMedCrossRef

Pan H, Wang H, Zhu L, Mao L, Qiao L, Su X (2011) Depletion of nrf2 enhances inflammation induced by oxyhemoglobin in cultured mice astrocytes. Neurochem Res 36(12):2434–2441PubMedCrossRef

Pasco JA, Jacka FN, Williams LJ, Henry MJ, Nicholson GC, Kotowicz MA, Berk M (2010) Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosom 79(5):323–325PubMedCrossRef

Passi S, Stancato A, Aleo E, Dmitrieva A, Littarru GP (2003) Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors 18(1–4):113–124PubMedCrossRef

Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto ZA, Wang YT, Collingridge GL (2008) The role of GSK-3 in synaptic plasticity. Br J Pharmacol 153:S428–S437PubMedCrossRef

Periyasamy S, Sánchez ER (2002) Antagonism of glucocorticoid receptor transactivity and cell growth inhibition by transforming growth factor-beta through AP-1-mediated transcriptional repression. Int J Biochem Cell Biol 34(12):1571–1585PubMedCrossRef

Piantadosi CA, Withers CM, Bartz RR, MacGarvey NC, Fu P, Sweeney TE, Welty-Wolf KE, Suliman HB (2011) Heme oxygenase-1 couples activation of mitochondrial biogenesis to anti-inflammatory cytokine expression. J Biol Chem 286(18):16374–16385PubMedCrossRef

Plein H, Berk M (2000) Changes in the platelet intracellular calcium response to serotonin in patients with major depression treated with electroconvulsive therapy: state or trait marker status. Int Clin Psychopharmacol 15(2):93–98PubMedCrossRef

Polter AM, Li X (2011) Glycogen synthase kinase-3 is an intermediate modulator of serotonin neurotransmission. Front Mol Neurosci 4:31PubMedCrossRef

Popoli M (2009) Agomelatine: innovative pharmacological approach in depression. CNS Drugs 23(Suppl 2):27–34PubMedCrossRef

Qian HR, Yang Y (2009) Neuron differentiation and neuritogenesis stimulated by N-acetylcysteine (NAC). Acta Pharmacol Sin 30(7):907–912PubMedCrossRef

Quiroz JA, Gray NA, Kato T, Manji HK (2008) Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33(11):2551–2565PubMedCrossRef

Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA, Hamilton RL, Chu CT, Jordan-Sciutto KL (2007) Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 66:75–85PubMedCrossRef

Rasola A, Sciacovelli M, Chiara F, Pantic B, Brusilow WS, Bernardi P (2010) Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. Proc Natl Acad Sci USA 107(2):726–731PubMedCrossRef

Ray WJ Jr, Szymanki ES, Ng L (1978) The binding of lithium and of anionic metabolites to phosphoglucomutase. Biochim Biophys Acta 522(2):434–442PubMed

Rehani K, Wang H, Garcia CA, Kinane DF, Martin M (2009) Toll-like receptor-mediated production of IL-1Ra is negatively regulated by GSK3 via the MAPK ERK1/2. J Immunol 182(1):547–553PubMed

Rodríguez-Hernández A, Cordero MD, Salviati L, Artuch R, Pineda M, Briones P, Gómez Izquierdo L, Cotán D, Navas P, Sánchez-Alcázar JA (2009) Coenzyme Q deficiency triggers mitochondria degradation by mitophagy. Autophagy 5(1):19–32PubMedCrossRef

Rojo AI, Rada P, Egea J, Rosa AO, Lopez MG, Cuadrado A (2008a) Functional interference between glycogen synthase kinase-3 beta and the transcription factor Nrf2 in protection against kainate-induced hippocampal cell death. Mol Cell Neurosci 39:125–132PubMedCrossRef

Rojo AI, Sagarra MR, Cuadrado A (2008b) GSK-3β down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J Neurochem 105(1):192–202PubMedCrossRef

Romeo L, Intrieri M, D’Agata V, Mangano NG, Oriani G, Ontario ML, Scapagnini G (2009) The major green tea polyphenol, (−)-epigallocatechin-3-gallate, induces heme oxygenase in rat neurons and acts as an effective neuroprotective agent against oxidative stress. J Am Coll Nutr 28(Suppl):492S–499SPubMed

Rosa AO, Kaster MP, Binfaré RW, Morales S, Martín-Aparicio E, Navarro-Rico ML, Martínez A, Medina M, García AG, Lopez MG, Rodrigues ALS (2008) Antidepressant-like effects of the novel thiadiazolidinone NP031115 in mice. Prog Neuro Psychopharm Biol Psychiatry 32:1549–1556CrossRef

Rosenberg G (2007) The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci 64(16):2090–2103

Rowe MK, Wiest C, Chuang DM (2007) GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev 31:920–931PubMedCrossRef

Sachdeva AK, Kuhad A, Chopra K (2011) Epigallocatechin gallate ameliorates behavioral and biochemical deficits in rat model of load-induced chronic fatigue syndrome. Brain Res Bull 86(3–4):165–172PubMedCrossRef

Sakić B, Szechtman H, Braciak T, Richards C, Gauldie J, Denburg JA (1997) Reduced preference for sucrose in autoimmune mice: a possible role of interleukin-6. Brain Res Bull 44(2):155–165PubMedCrossRef

Sakić B, Gauldie J, Denburg JA, Szechtman H (2001) Behavioral effects of infection with IL-6 adenovector. Brain Behav Immun 15(1):25–42PubMedCrossRef

Samavati L, Rastogi R, Du W, Huttemann M, Fite A, Franchi L (2009) STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria. Mol Immunol 46:1867–1877PubMedCrossRef

Sandi C (2004) Stress, cognitive impairment and cell adhesion molecules. Nat Rev Neurosci 5:917–930PubMedCrossRef

Sandi C, Bisaz R (2007) A model for the involvement of neural cell adhesion molecules in stress-related mood disorders. Neuroendocrinology 85(3):158–176PubMedCrossRef

Scapagnini G, D’Agata V, Calabrese V, Pascale A, Colombrita C, Alkon D, Cavallaro S (2002) Gene expression profiles of heme oxygenase isoforms in the rat brain. Brain Res 954(1):51–59PubMedCrossRef

Scapagnini G, Caruso C, Calabrese V (2010) Therapeutic potential of dietary polyphenols against brain ageing and neurodegenerative disorders. Adv Exp Med Biol 698:27–35PubMedCrossRef

Scapagnini G, Caruso C, Calabrese V (2011a) Therapeutic potential of dietary polyphenols against brain ageing and neurodegenerative disorders. Adv Exp Med Biol 698:27–35CrossRef

Scapagnini G, Vasto S, Abraham NG, Caruso C, Zella D, Fabio G (2011b) Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol 44(2):192–201PubMedCrossRef

Schmidt HD, Duman RS (2007) The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 18(5–6):391–418PubMedCrossRef

Schmidt AJ, Heiser P, Hemmeter UM, Krieg JC, Vedder H (2008) Effects of antidepressants on mRNA levels of antioxidant enzymes in human monocytic U-937 cells. Prog Neuropsychopharmacol Biol Psychiatry 32(6):1567–1573PubMedCrossRef

Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H (1995) Cytokine production and serum proteins in depression. Scand J Immunol 41(6):534–538PubMedCrossRef

Shah PJ, Glabus MF, Goodwin GM, Ebmeier KP (2002) Chronic, treatment-resistant depression and right fronto-striatal atrophy. Br J Psychiatr 180:434–440CrossRef

Shaldubina A, Agam G, Belmaker RH (2001) The mechanism of lithium action: state of the art, ten years later. Prog Neuropsychopharmacol Biol Psychiatry 25(4):855–866PubMedCrossRef

Shao L, Martin MV, Watson SJ, Schatzberg A, Akil H, Myers RM, Jones EG, Bunney WE, Vawter MP (2008) Mitochondrial involvement in psychiatric disorders. Ann Med 40(4):281–295PubMedCrossRef

Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, Murphy TH (2003) Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 23:3394–3406PubMed

Sirianni RW, Olausson P, Chiu AS, Taylor JR, Saltzman WM (2010) The behavioral and biochemical effects of BDNF containing polymers implanted in the hippocampus of rats. Brain Res 1321:40–50PubMedCrossRef

Siwek M, Dudek D, Paul IA, Sowa-Kucma M, Zieba A, Popik P, Pilc A, Nowak G (2009) Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J Affect Disord 118:187–195PubMedCrossRef

Smith RAJ, Murphy MP (2011) Mitochondrial-targeted antioxidants as therapies. Disc Med 11(57):106–114

Smith MA, Makino S, Kvetnansky R, Post RM (1995) Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 15:1768–1777PubMed

Song C, Wang H (2011) Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 35(3):760–768PubMedCrossRef

Song C, Horrobin DF, Leonard BE (2006) The comparison of changes in behavior, neurochemistry, endocrine, and immune functions after different routes, doses and durations of administrations of IL-1beta in rats. Pharmacopsychiatry 39(3):88–99PubMedCrossRef

Stafford L, Berk M (2011) The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry 72(9):1229–1235PubMedCrossRef

Stambolic V, Woodgett JR (1994) Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J 303(3):701–704PubMed

Stavrovskaya IG, Narayanan MV, Zhang W, Krasnikov BF, Heemskerk J, Young SS, Blass JP, Brown AM, Beal MF, Friedlander RM, Kristal BS (2004) Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med 200(2):211–222PubMedCrossRef

Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY, Uylings HB, Friedman L, Rajkowska G (2004) Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 56(9):640–650PubMedCrossRef

Stork C, Renshaw PF (2005) Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 10(10):900–919PubMedCrossRef

Sun Z, Zhang S, Chan JY, Zhang DD (2007) Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2. Mol Cell Biol 27(18):6334–6349PubMedCrossRef

Suomalainen A, Majander A, Haltia M, Somer H, Lönnqvist J, Savontaus ML, Peltonen L (1992) Multiple deletions of mitochondrial DNA in several tissues of a patient with severe retarded depression and familial progressive external ophthalmoplegia. J Clin Invest 90(1):61–66PubMedCrossRef

Szewczyk B, Poleszak E, Sowa-Kucma M, Siwek M, Dudek D, Ryszewska-Pokraśniewicz B, Radziwoń-Zaleska M, Opoka W, Czekaj J, Pilc A, Nowak G (2008) Antidepressant activity of zinc and magnesium in view of current hypotheses of antidepressant action. Pharmacol Rep 60:588–599PubMed

Szewczyk B, Kubera M, Nowak G (2011) The role of zinc in neurodegenerative inflammatory pathways in depression. Progr Neuro Psychopharmacol Biol Psychiatry 35:693–701CrossRef

Tsuboi H, Tatsumi A, Yamamoto K, Kobayashi F, Shimoi K, Kinae N (2006) Possible connections among job stress, depressive symptoms, lipid modulation and antioxidants. J Affect Disord 91(1):63–70PubMedCrossRef

Turner CA, Akil H, Watson SJ, Evans SJ (2006) The fibroblast growth factor system and mood disorders. Biol Psychiatry 59(12):1128–1135PubMedCrossRef

Ungvari Z, Sonntag WE, de Cabo R, Baur JA, Csiszar A (2011) Mitochondrial protection by resveratrol. Exerc Sport Sci Rev 39(3):128–132PubMedCrossRef

Vaidya VA, Duman RS (2001) Depression—emerging insights from neurobiology. Br Med Bull 57:61–79PubMedCrossRef

Valvassori SS, Rezin GT, Ferreira CL, Moretti M, Gonçalves CL, Cardoso MR, Streck EL, Kapczinski F, Quevedo J (2010) Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J Psychiatr Res 44(14):903–909PubMedCrossRef

Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA (2008) Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 50:13574–13581CrossRef

Venugopal R, Jaiswal AK (1996) Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 93(25):14960–14965PubMedCrossRef

Wang X, Ryter SW, Dai C, Tang ZL, Watkins SC, Yin XM, Song R, Choi AM (2003) Necrotic cell death in response to oxidant stress involves the activation of the apoptogenic caspase-8/bid pathway. J Biol Chem 278(31):29184–29191PubMedCrossRef

Wang X, Zhang J, Kim HP, Wang Y, Choi AM, Ryter SW (2004) Bcl-XL disrupts death-inducing signal complex formation in plasma membrane induced by hypoxia/reoxygenation. FASEB J 18(15):1826–1833PubMedCrossRef

Wang D, Noda Y, Tsunekawa H, Zhou Y, Miyazaki M, Senzaki K, Nabeshima T (2007) Behavioural and neurochemical features of olfactory bulbectomized rats resembling depression with comorbid anxiety. Behav Brain Res 178(2):262–273PubMedCrossRef

Wang JF, Shao L, Sun X, Young LT (2009) Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 11(5):523–529PubMedCrossRef

Wang H, Brown J, Martin M (2011a) Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine 53:130–140PubMedCrossRef

Wang X, de Rivero Vaccari JP, Wang H, Diaz P, German R, Marcillo AE, Keane RW (2011b) Activation of the nuclear factor E2-related factor 2/antioxidant response element pathway is neuroprotective after spinal cord injury. J Neurotrauma Sep 21 (Epub ahead of print)

Wang Y, Yang F, Liu YF, Gao F, Jiang W (2011c) Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. Neurosci Lett 499(2):74–79PubMedCrossRef

Wang Y, Xiao Z, Liu X, Berk M (2011d) Venlafaxine modulates depression-induced behaviour and the expression of Bax mRNA and Bcl-xl mRNA in both hippocampus and myocardium. Hum Psychopharmacol 26(2):95–101PubMedCrossRef

Wei QY, Chen WF, Zhou B, Yang L, Liu ZL (2006) Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochim Biophys Acta 1760(1):70–77PubMedCrossRef

Whatley SA, Curti D, Marchbanks RM (1996) Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res 21:995–1004PubMedCrossRef

Whittle BJ, Varga C, Posa A, Molnar A, Collin M, Thiemermann C (2006) Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. Br J Pharmacol 147:575–582PubMedCrossRef

Witte ME, Geurts JJ, de Vries HE, van der Valk P, van Horssen J (2010) Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? Mitochondrion 10(5):411–418PubMedCrossRef

Wojda U, Salinska E, Kuznicki J (2008) Calcium ions in neuronal degeneration. IUBMB Life 60(9):575–590PubMedCrossRef

Wrynn AS, Mac Sweeney CP, Franconi F, Lemaire L, Pouliquen D, Herlidou S, Leonard BE, Gandon J, de Certaines JD (2000) An in vivo magnetic resonance imaging study of the olfactory bulbectomized rat model of depression. Brain Res 879(1-2):193–199PubMedCrossRef

Xia Z, DePierre JW, Nassberger L (1996) Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology 34:27–37PubMedCrossRef

Xia ZW, Zhong WW, Xu LQ, Sun JL, Shen QX, Wang JG, Shao J, Li YZ, Yu SC (2006) Heme oxygenase-1-mediated CD4+CD25high regulatory T cells suppress allergic airway inflammation. J Immunol 177(9):5936–5945PubMed

Xu Y, Ku BS, Yao HY, Lin YH, Ma X, Zhang YH, Li XJ (2005) Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav 82(1):200–206PubMedCrossRef

Xu Y, Ku B, Cui L, Li X, Barish PA, Foster TC, Ogle WO (2007) Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res 1162:9–18PubMedCrossRef

Xu Y, Wang Z, You W, Zhang X, Li S, Barish PA, Vernon MM, Du X, Li G, Pan J, Ogle WO (2010) Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system. Eur Neuropsychopharmacol 20(6):405–413PubMedCrossRef

Yamamoto T, Suzuki T, Kobayashi A, Wakabayashi J, Maher J, Motohashi H, Yamamoto M (2008) Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 28(8):2758–2770PubMedCrossRef

York JD, Ponder JW, Majerus PW (1995) Definition of a metal-dependent/Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. Proc Natl Acad Sci USA 92(11):5149–5153PubMedCrossRef

Zafir A, Ara A, Banu N (2009) Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 33(2):220–228PubMedCrossRef

Zhang WH, Wang H, Wang X, Narayanan MV, Stavrovskaya IG, Kristal BS, Friedlander RM (2008) Nortriptyline protects mitochondria and reduces cerebral ischemia/hypoxia injury. Stroke 39(2):455–462PubMedCrossRef

Springer Medizin

New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors

Abstract

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Inflammation in neurological and psychiatric diseases

The role of inflammatory processes in Alzheimer’s disease

Chemical genetics of neuroinflammation: natural and synthetic compounds as microglial inhibitors

Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated in vitro blood culture from depressed patients

NSAIDs in the treatment and/or prevention of neurological disorders

Anti-inflammatory properties and pharmacological induction of Hsp70 after brain injury